Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 169, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103531
Keywords
Immunotherapy; Lung cancer; Pseudoprogression; Immune checkpoint inhibitors
Categories
Funding
- Funds of Talent Recruitment and Development of The Second Affiliated Hospital of Hainan Medical University
- Foundation of Educational Commission of Liaoning Province of China [LQNK201714]
Ask authors/readers for more resources
The occurrence of pseudoprogression in lung cancer due to the application of immunotherapy has complicated clinical evaluation and management, highlighting the need for a better understanding of its mechanisms and strategies for differentiation.
Lung cancer has attracted much attention because of its high morbidity and mortality worldwide. The advent of immunotherapy approaches, especially the application of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of lung cancer, but a novel and unexpected pattern of treatment response-- pseudoprogression, has been observed simultaneously which complicates the routine clinical evaluation and management. However, manifestations of pseudoprogression vary and there are many disputes on immune-related response assessment and corresponding treatments for lung cancer. Therefore, we summarized the possible mechanisms, clinical manifestations and corresponding treatment measures of pseudoprogression in lung cancer, as well as potential methods to differentiate pseudoprogression from true tumor progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available